|
pubmed:abstractText |
The primary objective was to study the antitumor activity of prolonged subcutaneous dosing of systemic 852A, a Toll-like receptor-7 agonist (TLR-7), in recurrent breast, ovarian and cervix cancer. Secondary objectives included assessment of safety and immune system activation.
|
|
pubmed:affiliation |
Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, MMC 395 420 Delaware St. SE., Minneapolis, MN, 55455, USA.
|
